Latest Financial Results

Q2 2022

Quarterly Results

Ended Jun 30, 2022

Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.
Price
Change
Volume
Day Range
52 Week Range

Company Overview

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

The Company is also developing its personalized CAR T platform technology, XCART™, to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-Cell lymphomas.

Contact Information

Investor Relations
JTC Team, LLC.
Jenene Thomas
T: 833-475-8247
xbio@jtcir.com

Transfer Agent
Empire Stock Transfer, Inc.
1859 Whitney Mesa Drive
Henderson, NV 89014
T: 702-818-5898